Ralf Liebhold / Shutterstock.com
5 July 2022
Fed Circuit to address cannabis clash
The dispute centres on a process for extracting CBD from cannabis plant material, which anticipates the use of CBD as an anti-epileptic treatment.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
24 December 2020 Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.
Editor's picks
Editor's picks
Americas
24 December 2020 Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.
Americas
24 December 2020 Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.